These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 33489083)
41. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin. Majlath Z; Obal I; Vecsei L CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624 [TBL] [Abstract][Full Text] [Related]
42. Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review. Sellers J; Darby RR; Farooque A; Claassen DO Drugs Aging; 2019 Jul; 36(7):647-653. PubMed ID: 30924099 [TBL] [Abstract][Full Text] [Related]
43. Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study. Layton JB; Forns J; Turner ME; Dempsey C; Bartsch JL; Anthony MS; Danysh HE; Ritchey ME; Demos G Drugs Real World Outcomes; 2022 Mar; 9(1):9-22. PubMed ID: 34718963 [TBL] [Abstract][Full Text] [Related]
44. The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin. Mathis MV; Muoio BM; Andreason P; Avila AM; Farchione T; Atrakchi A; Temple RJ J Clin Psychiatry; 2017 Jun; 78(6):e668-e673. PubMed ID: 28493654 [TBL] [Abstract][Full Text] [Related]
45. Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed. Citrome L; Norton JC; Chi-Burris K; Demos G CNS Spectr; 2018 Jun; 23(3):228-238. PubMed ID: 29098976 [TBL] [Abstract][Full Text] [Related]
46. Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis. Sarva H; Henchcliffe C Ther Adv Neurol Disord; 2016 Nov; 9(6):462-473. PubMed ID: 27800022 [TBL] [Abstract][Full Text] [Related]
47. Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios. Hubbard D; Hacksell U; McFarland K Behav Pharmacol; 2013 Oct; 24(7):628-32. PubMed ID: 23969614 [TBL] [Abstract][Full Text] [Related]
48. Update on the treatment of Parkinson's disease psychosis: role of pimavanserin. Combs BL; Cox AG Neuropsychiatr Dis Treat; 2017; 13():737-744. PubMed ID: 28331324 [TBL] [Abstract][Full Text] [Related]
49. Parkinson's Disease Psychosis and the Marketing of Pimavanserin. Daeschler D; Fugh-Berman A Int J Soc Determinants Health Health Serv; 2024 Jul; 54(3):272-284. PubMed ID: 38592164 [TBL] [Abstract][Full Text] [Related]
50. Pimavanserin: A Truly Effective Treatment for Parkinson's Disease Psychosis? A Review of Interventions. Heim B; Peball M; Krismer F; Djamshidian A; Seppi K Neuropsychiatr Dis Treat; 2023; 19():1303-1312. PubMed ID: 37274140 [TBL] [Abstract][Full Text] [Related]
51. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis. Panchal SC; Ondo WG Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325 [TBL] [Abstract][Full Text] [Related]
52. Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics. Rajagopalan K; Rashid N; Kumar S; Doshi D J Med Econ; 2023; 26(1):34-42. PubMed ID: 36444507 [TBL] [Abstract][Full Text] [Related]
53. Evaluating pimavanserin tartrate as a treatment in Parkinson's disease. Müller T Expert Opin Pharmacother; 2024 Oct; ():. PubMed ID: 39403823 [TBL] [Abstract][Full Text] [Related]